-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16

Benzinga·07/24/2026 12:40:07
Listen to the news
Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.